IP Verse

Method For Treating Primary Insomnia - EP1441702

The patent EP1441702 was granted to Neurim Pharmaceuticals on May 10, 2017. The application was originally filed on Aug 12, 2002 under application number EP02760523A. The patent is currently recorded with a legal status of "Revoked".

EP1441702

NEURIM PHARMACEUTICALS
Application Number
EP02760523A
Filing Date
Aug 12, 2002
Status
Revoked
Jan 29, 2021
Grant Date
May 10, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ORIFARM GENERICSApr 8, 2020ZBM PATENTS APSINTERVENTION ADMISSIBLE
TEVA PHARMACEUTICALSFeb 12, 2018ELKINGTON AND FIFEWITHDRAWN
ASPIRE PHARMAFeb 9, 2018BROWNADMISSIBLE
GENERICS UKFeb 9, 2018COOKEADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONEP0513702
INTERNATIONAL-SEARCH-REPORTUS5498423
INTERNATIONAL-SEARCH-REPORTUS6423738
OPPOSITIONEP0513702
OPPOSITIONEP0565296
OPPOSITIONEP0724878
OPPOSITIONUS5498423
OPPOSITIONUS5707652
OPPOSITIONWO0149286
OTHERWO9407487
OTHERWO9503043
SEARCHEP0565296
SEARCHEP0724878
SEARCHWO0149286

Non-Patent Literature (NPL) Citations (92) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- BRUSCO ET AL, "Effect of melatonin in selected populations of sleep-disturbed patients", BIOLOGICAL SIGNAL AND RECEPTORS, KARGER, BASEL, CH, (19990101), vol. 8, ISSN 1422-4933, pages 126 - 131, XP002990655-
EXAMINATION- DUBOCOVICH M L ET AL, "Melatonin receptors", 19980101, (19980101), vol. 1, pages 187 - 193, XP002990671-
EXAMINATION- FAINSTEIN ET AL, "Effects of melatonin in elderly patients with sleep disturbance: a pilot study", CURRENT THERAPEUTIC RESEARCH, XX, XX, (19971201), vol. 58, no. 12, pages 990 - 1000, XP002990653-
EXAMINATION- HAIMOV I ET AL, "Melatonin replacement therapy elderly insomniacs", SLEEP, ALLEN PRESS, LAWRENCE, KS, US, (19950101), vol. 18, no. 7, ISSN 0161-8105, pages 598 - 603, XP002990657-
EXAMINATION- HAIMOV I ET AL, "Potential of melatonin replacement therapy in older patients with sleep disorders", DRUGS & AGING, ADIS INTERNATIONAL LTD, NZ, (19950101), vol. 7, no. 2, ISSN 1170-229X, pages 75 - 78, XP002990660-
EXAMINATION- HUGHES R J ET AL, "The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: asessment in a clinical trial of melatonin replacement", SLEEP, ALLEN PRESS, LAWRENCE, KS, US, (19980101), vol. 21, no. 1, ISSN 0161-8105, pages 52 - 68, XP002990675-
EXAMINATION- LEMOINE PATRICK ET AL, "Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects", JOURNAL OF SLEEP RESEARCH, (200712), vol. 16, no. 4, ISSN 0962-1105, pages 372 - 380-
EXAMINATION- ROTH T ET AL, "Consensus for the pharmacological management of insomnia in th enew millennium", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, MEDICON INTERNATIONAL, ESHER, GB, (20010101), vol. 55, no. 1, ISSN 1368-5031, page 10PAGES, XP002990688-
EXAMINATION- SILVA J A C E ET AL, "Special report from a symposium held by the WHO and the World Federation of sleep research societies: an overview of insomnias and related disorders - recognition, epidemiology and rational management", SLEEP, ALLEN PRESS, LAWRENCE, KS, US, (19960101), vol. 19, no. 5, ISSN 0161-8105, pages 412 - 416, XP002990669-
EXAMINATION- MONTI J M ET AL, "Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia", ARCHIVES OF GERONTOLOGY AND GERIATRICS, ELSEVIER, AMSTERDAM, NL, (19990101), vol. 28, doi:10.1016/S0167-4943(98)00129-0, ISSN 0167-4943, pages 85 - 98, XP002990661
EXAMINATION- UCHIKAWA O ET AL, "Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, (20020101), vol. 45, doi:10.1021/JM0201159, ISSN 0022-2623, pages 4222 - 4239, XP002990691
EXAMINATION- PERLIS M L ET AL, "Psychophysiological insomnia: the behavioural model and a neurocognitive perspective", JOURNAL OF SLEEP RESEARCH, BLACKWELL SCIENTIFIC, OXFORD, GB, (19970101), vol. 6, doi:10.1046/J.1365-2869.1997.00045.X, ISSN 0962-1105, pages 179 - 188, XP002990686
EXAMINATION- BUYSSE D J ET AL, "Diagnostic concordance for DSM-IV sleep disorders: a report from the APA/NIMH DSM-IV field trial", AMERICAN JOURNAL OF PSYCHIATRY, AMERICAN PSYCHIATRIC PUBLISHING, INC, US, (19940901), vol. 151, no. 9, ISSN 0002-953X, pages 1351 - 1360, XP008152789
OPPOSITION- "Annex I Summary of Product Characteristics", European Medicines Agency, (20120000), pages 1 - 10, XP055464542-
OPPOSITION- A.R. Gennaro, Remington: The Science and Practice of Pharmacy, 20th ed., (20000000), pages 910 - 914, XP055465494-
OPPOSITION- BRUSCO et al., "Effect of melatonin in selected populations of sleep-disturbed patients", BIOLOGICAL SIGNAL AND RECEPTORS, KARGER, BASEL, CH, (19990000), vol. 8, pages 126 - 131, XP002990655-
OPPOSITION- BRUSCO et al., "Effect of melatonin in selected populations of sleep-disturbed patients", BIOL. SIGNALS RECEPT., (19990000), vol. 8, pages 126 - 131, XP002990655-
OPPOSITION- Dawson et al., "Shift Work and Sleep Deprivation - Improving Adaptation to Simulated Night Shift: Timed Exposure to Bright Light Versus Daytime Melatonin Administration", Sleep, (19950000), vol. 18, no. 1, pages 11 - 21, XP055465457-
OPPOSITION- DUBOCOVICH M L et al., "Melatonin receptors", The IUPHAR Compendium of Receptor Characterization and Classification, (19980000), vol. 1, pages 187 - 193, XP002990671-
OPPOSITION- EMA, "Guideline on medicinal products for the treatment of insomnia", (20110217), pages 1 - 21, URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC500102351.pdf, XP055465468-
OPPOSITION- European Medicines Agency, "Annex I Summary of Product Characteristics", (20120629), pages 1 - 10, XP055464542-
OPPOSITION- European Medicines Agency, "Assesment Report for Circadin", London, UK, (20070000), pages 1 - 52, URL: http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_- _Scientific_Discussion/human/000695/WC50002680.pdf, (20131001), XP055465425-
OPPOSITION- FAINSTEIN et al., "Effects of melatonin in elderly patients with sleep disturbance: a pilot study", CURRENT THERAPEUTIC RES., (19970000), vol. 58, no. 12, pages 990 - 1000, XP002990653-
OPPOSITION- FAINSTEIN et al., "Effects of melatonin in elderly patients with sleep disturbance: a pilot study", CURRENT THERAPEUTIC RESEARCH, (19971200), vol. 58, no. 12, pages 990 - 1000, XP002990653-
OPPOSITION- GARFINKEL D. et al., "Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach", DEPT OF NEUROBIOCHEMISTRY, (19970000), pages 1 - 22, XP002990672-
OPPOSITION- Haimov et al., "Melatonin replacement therapy elderly insomniacs", Sleep, vol. 18, no. 7, pages 598 - 603, XP002990657-
OPPOSITION- HAIMOV et al., "Melatonin replacement therapy of elderly insomniacs", SLEEP, LAWRENCE, KS, US, (19950000), vol. 18, no. 7, pages 598 - 603, XP002990657-
OPPOSITION- HAIMOV I et al., "Melatonin replacement therapy elderly insomniacs", SLEEP, (19950000), vol. 18, no. 7, pages 598 - 603, XP002990657-
OPPOSITION- HAIMOV I et al., "Potential of melatonin replacement therapy in older patients with sleep disorders", DRUGS & AGING, (19950000), vol. 7, no. 2, pages 75 - 78, XP002990660-
OPPOSITION- HUGHES R J et al., "The role of melatonin and eircadian phase in age-related sleep-maintenance insomnia: asessment in a clinical trial of melatonin replacement", SLEEP, (19980000), vol. 21, no. 1, pages 52 - 68, XP002990675-
OPPOSITION- LEMOINE PATRICK et al., "Prolonged-release melatonin improves sleep quality and morning aler tness in insomnia patients aged 55 years and older and has no withdrawal effects", JOURNAL OF SLEEP RESEARCH, (20070000), vol. 16, no. 4, pages 372 - 380, XP055465436-
OPPOSITION- Micheal E. Aulton, Pharmaceutics: The science of dosage form design, (19880000), pages 315 - 317, XP055465490-
OPPOSITION- PABLOS-MENDEZ A, "Run-in Periods in Randomized Trials: Implications for the Application of Results in Clinical Practice", JAMA, (19980000), vol. 279, no. 3, pages 222 - 225, XP055465467-
OPPOSITION- ROTH et al., "Consensus for the pharmacological management of insomnia in the new millennium", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ICJP), MEDICON INTERNATIONAL, ESHER, GB, (20010100), vol. 55, no. 1, pages 1 - 10, XP002990688-
OPPOSITION- ROTH T et al., "Consensus for the pharmacological management of insomnia in the new millennium", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, (20010100), vol. 55, no. 1, pages 1 - 10, XP002990688-
OPPOSITION- SILVA J A C E et al., "Special report from a symposium held by the WHO and the World Federation of sleep research societies: an overview of insomnias and related disorders - recognition, epidemiology and rational management", SLEEP, (19960000), vol. 19, no. 5, pages 412 - 416, XP002990669-
OPPOSITION- "Sleep better to feel better", Melatonex, Wayback Machine-
OPPOSITION- ZHDANOVA et al., "Melatonin: a sleep-promoting hormone", SLEEP, (19970000), vol. 20, no. 10, pages 899 - 907, XP002990662-
OPPOSITION- CHAVALARIAS D. et al., "Evolution of Reporting P Values in the Biomedical Literature, 1990-2015", JAMA, (20160315), vol. 315, no. 11, pages 1141 - 1148, XP055465485
OPPOSITION- Garfinkel et al, "Improvement of sleep quality in elderly people by controlled-release melatonin", Lancet, (19950000), vol. 346, no. 8974, pages 541 - 544, XP002990656
OPPOSITION- Garfinkel et al., "Improvement of sleep quality in elderly people by controlled-release melatonin", Lancet, (19950000), vol. 346, no. 8974, pages 541 - 544, XP002990656
OPPOSITION- GARFINKEL et al., "Improvement of sleep quality in elderly people by controlled- release melatonin", LANCET, (19950000), vol. 346, pages 541 - 544, XP002990656
OPPOSITION- MONT! J M et al., "Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia", ARCHIVES OF GERONTOLOGY AND GERIATRICS, (19990000), vol. 28, pages 85 - 98, XP002990661
OPPOSITION- UCHIKAWA O et al., "Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists", JOURNAL OF MEDICINAL CHEMISTRY, (20020101), vol. 45, pages 4222 - 4239, XP002990691
OPPOSITION- PERLIS M L et al., "Psychophysiological insomnia: the behavioural model and a neurocognitive perspective", JOURNAL OF SLEEP RESEARCH, (19970000), vol. 6, pages 179 - 188, XP002990686
OPPOSITION- Bubenik et al., "PROSPECTS OF THE CLINICAL UTILIZATION OF MELATONIN", Biological Signals and Receptors, (19980000), vol. 7, pages 195 - 219, XP000893109
OPPOSITION- "The use of melatonin for the treatment of insomnia", Biological Signals and Receptors, (19990000), vol. 8, no. 1-2, pages 84 - 9, XP002990654
OPPOSITION- ZISAPEL, "The use of melatonin for the treatment of insomnia", BIOLOGICAL SIGNALS AND RECEPTORS, (19990000), vol. 8, pages 84 - 89, XP002990654
OPPOSITION- BUYSSE D J et al., "Diagnostic concordance for DSM-IV sleep disorders: a report from the APA/NIMH DSM-IV field trial", AMERICAN JOURNAL OF PSYCHIATRY, (19940900), vol. 151, no. 9, pages 1351 - 1360, XP008152789
OTHER- ATTENBURROW M.E.J. ET AL., "Case-control study of evening melatonin concentration in primary insomnia", BMJ, (19960518), vol. 312, pages 1263 - 1264, XP002990666-
OTHER- BONNET M.H., ARAND D.L., "Physiological activation in patients with sleep state misperception", PSYCHOSOM MED, (1997), vol. 59, no. 5, pages 533 - 540, XP002990668-
OTHER- BRUSCO ET AL., "Effect of melatonin in selected populations of sleep-disturbed patients", BIOL. SIGNALS RECEPT., (1999), vol. 8, pages 126 - 131, XP002990655-
OTHER- CUBOCOVICH M.L. ET AL., "Melatonin receptors", THE IUPHAR COMPENDIUM OF RECEPTOR CHARACTERIZATION AND CLASSIFICATION, (1998), vol. 1, pages 187 - 193, XP002990671-
OTHER- DIJK D-J., CAJOCHEN C., "Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG", J OF BIOLOGICAL RHYTHMS, (199712), vol. 12, no. 6, pages 627 - 635, XP002990667-
OTHER- FAINSTEIN ET AL., "Effects of melatonin in elderly patients with sleep disturbance: a pilot study", CURRENT THERAPEUTIC RES., (199712), vol. 58, no. 12, pages 990 - 1000, XP002990653-
OTHER- GARFINKEL D. ET AL., "Facilitation of BZD discontinuation by melatonin: a new clinical approach", DEPT OF NEUROBIOCHEMISTRY, TEL AVIV UNIVERSITY, (1997), page 22 PAGES, XP002990672-
OTHER- HAHM H. ET AL., "Comparison of melatonin products against USP's nutritional supplements standards and other criteria", J AM PHARM ASSOC, (1999), vol. 39, no. 1, pages 27 - 31, XP002990665-
OTHER- HAIMOV I. ET AL., "Melatonin replacement therapy elderly insomniacs", SLEEP, (1995), vol. 18, no. 7, pages 598 - 603, XP002990657-
OTHER- HAIMOV I., LAVIE P., "Potential of melatonin replacement therapy in older patients with sleep disorders", DRUGS AND AGING, (1995), vol. 7, no. 2, pages 75 - 78, XP002990660-
OTHER- HAYS R. ET AL., "Development of brief surveys to assess restorative sleep and daytime consequences of sleep", SLEEP, ABSTRACT SUPPLEMENT, (2004), vol. 27, page A349, XP002990673-
OTHER- HUGHES R.J. ET AL., "The role of melatonin and circadian phase in age-related sleep-maintenance insomnia: asessment in a clinical trial of melatonin replacement", SLEEP, (1998), vol. 21, no. 1, pages 52 - 68, XP002990675-
OTHER- LADER M.H., "Abuse potential, tolerance and dependence on chronic anxiolytic treatment", INTERNATIONAL ACADEMY FOR BIOMEDICAL AND DRUG RESEARCH, (1992), vol. 3, pages 46 - 54, XP002990676-
OTHER- LANE E.A., MOSS H.B., "Pharmacokinetics of melatonin in man: first pass hepatic metabolism", J OF CLINICAL ENDOCRINOLOGY AND METABOLISM, (1985), vol. 61, no. 6, pages 1214 - 1216, XP002990677-
OTHER- LEIPZIG R.M. ET AL., "Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs", JAGS, (1999), vol. 47, pages 30 - 39, XP002990678-
OTHER- LITTNER M. ET AL., "Practice parameters for using polysomnography to evaluate insomnia: an update", SLEEP, (2003), vol. 26, no. 6, pages 754 - 760, XP002990679-
OTHER- MINTZER M.Z., GRIFFITHS R.R., "Selective effects of zolpidem on human memory functions", J OF PSYCHOPHARMACOLOGY, (1999), vol. 13, no. 1, pages 18 - 31, XP002990681-
OTHER- ROTH T. ET AL., "Consensus for the pharmacological management of insomnia in th enew millennium", INT J CLIN PRACT, (2001), vol. 55, no. 1, page 10 PAGES, XP002990688-
OTHER- SILVA J.A.C.E. ET AL., "Special report from a symposium held by the WHO and the World Federation of sleep research societies: an overview of insomnias and related disorders - recognition, epidemiology and rational management", SLEEP, (1996), vol. 19, no. 5, pages 412 - 416, XP002990669-
OTHER- ZHDANOVA I.V. ET AL., "Melatonin: a sleep-promoting hormone", SLEEP, (1997), vol. 20, no. 10, pages 899 - 907, XP002990662-
OTHER- OHAYON M.M., "Prevalence and correlates of nonrestorative sleep complaints", ARCH INTERN. MED., (20050110), vol. 165, pages 35 - 41, XP002990684
OTHER- MORIN C.M. ET AL., "Behavioral and pharmacological therapies for late-life insomnia", JAMA, (19990317), vol. 281, no. 11, pages 991 - 999, XP002990683
OTHER- HOHAGEN F. ET AL., "Prevalence and treatment of insomnia in general practice", EUR ARCH PSYCHIATRY CLIN NEUROSCI, (1993), vol. 242, pages 329 - 336, XP002990674
OTHER- ATTENBURROW M.E.J. ET AL., "Low dose melatonin improves sleep in healthy middle-aged subjects", PSYCHOPHARMACOLOGY, (1996), vol. 126, pages 179 - 181, XP002990658
OTHER- PARRINO L., TERZANO M.G., "Polysomnographic effects of hypnotic drugs", PSYCHOPHARMACOLOGY, (1996), vol. 126, pages 1 - 1, XP002990685
OTHER- ZHDANOVA ET AL., "Sleep-inducing effects of low doses of melatonin ingested in the evening", CLINICAL PHARMACOLOGY AND THERAPEUTICS, (1995), vol. 57, no. 5, pages 552 - 558, XP002990659
OTHER- TUREK F.W., GILLETTE M.U., "Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists", SLEEP MEDICINE, (2004), vol. 5, pages 523 - 532, XP004633333
OTHER- RUSH C.R., "Behavioral pharmacology of zolpidem relative to benzodiazepines: a review", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, (1998), vol. 61, no. 3, pages 253 - 269, XP002990689
OTHER- GARFINKEL ET AL., "Improvement of sleep quality in elderly people by controlled-release melatonin", LANCET, (1995), vol. 346, pages 541 - 544, XP002990656
OTHER- BARBONE F. ET AL., "Association of road-traffic accidents with benzodiazepine use", LANCET, (1998), vol. 352, no. 9137, pages 1331 - 1336, XP004265705
OTHER- MONTI J.M. ET AL., "Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia", ARCHIVES OF GERONTOLOGY AND GERIATRICS, (1999), vol. 28, pages 85 - 98, XP002990661
OTHER- MILLET B. ET AL., "Prospects for anxiolytic therapy: a reflection from different viewpoints", DDT, (199810), vol. 3, no. 10, pages 471 - 479, XP002990680
OTHER- UCHIKAWA O. ET AL., "Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists", J. MED. CHEM., (2002), vol. 45, pages 4222 - 4239, XP002990691
OTHER- DELAGRANGE P. ET AL., "Therapeutic perspectives for melatonin agonists and antagonists", J OF NEUROENDOCRINOLOGY, (2003), vol. 15, pages 442 - 448, XP002990670
OTHER- PERLIS M.L. ET AL., "Psychophysiological insomnia: the behavioural model and a neurocognitive perspective", J. SLEEP RES., (1997), vol. 6, pages 179 - 188, XP002990686
OTHER- RIEMANN D. ET AL., "The guidelines for 'non-restorative sleep': relevance for the diagnosis and therapy of insomnia", SOMNOLOGIE, (2003), vol. 7, pages 66 - 76, XP002990687
OTHER- MORIN C.M., "Measuring outcomes in randomized clinical trials of insomnia treatments", SLEEP MEDICINE REVIEWS, (2003), vol. 7, no. 3, pages 263 - 279, XP002990682
OTHER- SHADER R.I. ET AL., "Use of benzodiazepines in anxiety disorders", THE NEW ENGLAND J OF MEDICINE, (19930513), vol. 328, no. 19, pages 1398 - 1405, XP002990690
OTHER- BUBENIK ET AL, "PROSPECTS OF THE CLINICAL UTILIZATION OF MELATONIN", BIOL. SIGNALS RECEPT, (1998), vol. 7, pages 195 - 219, XP000901003
OTHER- ZISAPEL ET AL., "The use of melatonin fo rth etreatment of insomnia", BIOLOGICAL SIGNALS AND RECEPTORS, (1999), vol. 8, pages 84 - 89, XP002990654
OTHER- SHAH J. ET AL., "Feasibility and functionality of OROS melatonin in healthy subjects", J CLIN PHARMACOL, (1999), vol. 39, pages 606 - 612, XP002990664
OTHER- WALACH H., "Placebo and placebo effects - a concise review", FOCUS ON ALTERNATIVE AND COMPLEMENTARY THERAPIES, (200306), vol. 8, no. 2, pages 178 - 187, XP002990692
OTHER- LEE B-J. ET AL., "Development and characterization of an oral controlled-release delivery system for melatonin", DRUG DEV. AND INDSTRIAL PHARMACY, (1996), vol. 22, no. 3, pages 269 - 274, XP002990663

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents